European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5
Aim is to predict novel catalysts using machine learning (ML) and artificial intelligence (AI) techniques
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
The addition of these two hospitals will provide increased access to specialized pediatric and perinatal care services in the geography
Wider reach for nutraceuticals portfolio in Europe, Turkey and Egypt
The Awards recognizes standout digital health & medical technology products and companies
Subscribe To Our Newsletter & Stay Updated
